Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b Open-Label Single Dose Safety, Tolerability, and Pharmacokinetics Study of RTX-134 in Adults With Phenylketonuria

NCT04110496 is registered in ClinicalTrials.gov with Rubius Therapeutics as lead sponsor.

NCT NCT04110496
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04110496 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b Open-Label Single Dose Safety, Tolerability, and Pharmacokinetics Study of RTX-134 in Adults With Phenylketonuria
Lead sponsor
Rubius Therapeutics
Phase
Phase 1
Overall status
Terminated
Start date
January 29, 2020
Completion date
December 1, 2022
Enrollment
1 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

phenylketonurias